ONO PHARMACEUTICAL, DAINIPPON SUMITOMO PHARMA TO ENTER INTO JOINT DEVELOPMENT AND MARKETING AGREEMENT

Ono Pharmaceutical and Dainipopn Sumitomo Pharma jointly announced on December 6 that they have singed a joint development and marketing agreement for limaprost alfadex, an oral prostaglandin E1 derivative indicated for the treatment of peripheral circulatory disturbance. Under the agreement terms, the two companies aim to obtain approval for an additional indication of limaprost alfadex, namely the treatment of cervical spondylosis.

Japan Corporate News Network (http://www.japancorp.net/Article.Asp?Art_ID=11464)